Xalnesiran with or without an Immunomodulator in Chronic Hepatitis BJinlin Hou, Edward Gane, Hong Tang et al.|New England Journal of Medicine|2024Cited by 77
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)Jinlin Hou, Tarik Asselah, Qing Xie et al.|Journal of Hepatology|2024Cited by 8